Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
14 August 2019 - 10:42PM
Edgar (US Regulatory)
UNITED STATES
|
|
OMB
APPROVAL
|
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
|
|
OMB
Number:
Expires:
Estimated
average burden
hours
per response
|
3235-0058
February
28, 2022
2.50
|
|
|
SEC
FILE NUMBER
000-52898
|
NOTIFICATION OF LATE FILING
|
|
CUSIP
NUMBER
|
(Check
one):
☐
Form 10-K
☐
Form
20-F
☐
Form 11-K
☒
Form
10-Q
☐
Form 10-D
☐
Form
N-SAR
☐
Form N-CSR
For Period
Ended:
June 30,
2019
☐
Transition
Report on Form 10-K
☐
Transition
Report on Form 20-F
☐
Transition
Report on Form 11-K
☐
Transition
Report on Form 10-Q
☐
Transition
Report on Form N-SAR
For the
Transition Period Ended:
Read Instruction (on back page) Before Preparing Form. Please Print
or Type.
Nothing in this form shall be construed to imply that the
Commission has verified any information contained
herein.
|
If the
notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification
relates:
PART I — REGISTRANT INFORMATION
Sunshine
Biopharma, Inc.
|
Full
Name of Registrant
|
|
Former
Name if Applicable
|
6500
Trans-Canada Highway, 4
th
Floor
|
Address
of Principal Executive Office
(Street and Number)
|
Point-Claire,
Quebec, Canada H9R 0A5
|
City,
State and Zip Code
|
PART II — RULES 12b-25(b) AND (c)
If the
subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b),
the following should be completed. (Check box if
appropriate)
|
(a)
|
The
reason described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date;
and
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule
12b-25(c) has been attached if applicable.
|
PART III — NARRATIVE
State
below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR,
N-CSR, or the transition report or portion thereof, could not be
filed within the prescribed time period.
Management requires
additional time to compile data to furnish to its professionals to
complete the Form 10-Q for the three months ended March 31,
2019.
SEC 1344
(04-09)
|
Persons
who are to respond to the collection of information contained
in
this
form are not required to respond unless the form displays a
currently
valid
OMB control number.
|
(Attach
extra Sheets if Needed)
PART IV — OTHER INFORMATION
(1)
Name and telephone
number of person to contact in regard to this
notification.
Andrew
I. Telsey
|
|
(303)
|
|
768-9221
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
Have all other periodic reports required under
Section 13 or 15(d) of the Securities Exchange Act of 1934 or
Section 30 of the Investment Company Act of 1940 during the
preceding 12 months or for such shorter period that the registrant
was required to file such report(s) been filed? If answer is no,
identify report(s).Yes
☒
No
⬜
(3)
Is it anticipated
that any significant change in results of operations from the
corresponding period for the last fiscal year will be reflected by
the earnings statement to be included in the subject report or
portion thereof?
Yes
☐
No
☒
If so,
attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a
reasonable estimate of the results cannot be made.
SUNSHINE BIOPHARMA,
INC.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
August 14, 2019
|
By:
/s/ Steve N.
Slilaty
Steve
N. Slilaty, Chief Executive Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or
by any other duly authorized representative. The name and title of
the person signing the form shall be typed or printed beneath the
signature. If the statement is signed on behalf of the registrant
by an authorized representative (other than an executive officer),
evidence of the representative’s authority to sign on behalf
of the registrant shall be filed with the form.